We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Surgical Innovations Group Plc | SUN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.50 | 0.50 | 0.50 | 0.50 | 0.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 03/4/2024 12:05 by justiceforthemany Contact investor relations.Ask why the results are still not out yet. |
Posted at 25/9/2023 20:38 by john148 It pains me to say but I'm afraid that this is an un-loved stock which has no value to any potential investor. Either there should be an overhaul of the B.O.D or the company taken private. |
Posted at 25/9/2023 12:06 by barrenwuffet2 I’m not sure SUN investors are getting behind the AMS and CMR newsfeed. |
Posted at 20/9/2023 07:54 by buywell3 Like Advanced Medical Solutions , Surgical Innovations also will play a major role in supplying the port access devices that the CMR Surgical Versius robot uses plus the ongoing consumables for 4 such devices needed for every operationThese are made by Surgical Innovations for CMR Surgical and also Surgical Innovations own the patent CMR Surgical has announced that it has worked with Surgical Innovations to develop YelloPort™ Elite 5mm, a new surgical port access system. The surgical port is made up of a reusable trocar and cannula, with single use valve, which minimises clinical waste and reduces the cost for hospitals when compared to traditional single-use surgical ports 1. David Marsh, Chief Executive Officer, Surgical Innovations, said: “We’re delighted to partner with CMR Surgical, a fellow British medical device company, to develop this new surgical Port Access System. Our ResposableTM products provide a high-quality hybrid instrument concept, with the clinical benefits of a small disposable element, reducing waste by at least 70% compared to fully disposable alternatives.” Mark Slack, Chief Medical Officer, CMR Surgical, said: “When we talk to hospitals and clinical teams, we hear how important it is for them to reduce the environmental impact of the surgical products and instruments they use. We want to partner with hospitals to reduce waste and cost, whilst advancing performance. Working with Surgical Innovations to develop this new port, we’ve been able to do just that.” -------------------- UK robotic surgery group raises $165mn It should be noted that CMR Surgical is planning to use the money raised to improve its product and to invest in its commercial capabilities to continue to gain market share. The monies were raised from existing investors of CMR Surgical. buywell adds As CMR Surgical gain market share , then so too will orders for the YelloPort™ Elite 5mm, which is a new resposable surgical port access system , that requires new consumables for each operation( made and supplied by surgical Innovations) whilst the major part of the device can be used again and again ( after the cleaning process within the hospital ) These reposable devices are what hospitals and healthcare services are turning to away from single use devices --- as they save them monies, whilst reducing materials going to reclamation/waste and also help meet climate gas emissions targets --- they form the backbone of Sustainable Healthcare Surgical Innovations are 100% owners of Elemental Healthcare dyor |
Posted at 29/3/2023 22:36 by buywell3 Look at this Final results presentation slides just made availableSales look set to accelerate from here into the rest of 2023 Market Environment – USA • YelloPort™ Elite 5mm and Optical trocar expected to have strong impact on US sales this year • Momentum now growing with some early account conversions Market Environment – UK • New account conversions underpinned by sustainability driving growth • Investment in key Sales & Marketing positions enhancing relationships in NHSSC* and private sector • Growth continues into Q1 with sales YTD up on 2022 Market Environment – EU • Strong return to growth, +28% • Sustainability resonates in some key market • Sales & Marketing training has renewed partner focus • New Distributor in Germany beginning to gain traction Market Environment – APAC • Continued growth up 24.6% • Japan underpins sales in the region and registration for 5mm Optical in Q4 will provide further opportunity • India will have positive impact on 2023 Market Environment – ROW • New distribution partner for Canada Market Environment – OEM Business • Strong sales growth up 45% • Collaboration with CMR to develop YP Elite opens opportunity within robotics and new territories • Ongoing supply chain issues disrupted sales to partners in Q1 • Strong order book for Q2 buywell notes --- this has nearly tripled since 2020 and looks set to grow further this year 2023 NPD Projects (under MDR): • Cost down initiatives on YelloPort Elite® range • Extension to Logi® Resposable® range, three new jaw configurations buywell note The extension to the Logi range above is expected to commence Q4 2023 At present it is just one cutter buywell expects various grasper types to be added to the range As buywell has posted 2024 looks set to be a bumper year if AMS LiquibandFix8 is added to the mix with PMA approval for sales to commence in the US --- could be as early at august 2023 --- sales of CMR Surgical Versius robots continues to gain traction = very good for Surgical Innovations Elite 5mm sales + consumables ongoing dyor |
Posted at 21/9/2021 23:03 by john148 A few years ago this was a speculative share with a lot of promise and I was fortunate to ride the wave when the share price climbed to 11p plus. Today I see it as a totally unexciting stock which is unlikely to provide any new investor(s) with a return on their investment. I had hoped that AMS would make an offer and relieve me of the remaining shares I hold in this company but I now think it unlikely. |
Posted at 30/3/2021 10:41 by jmf69 There was a question in the investor presentation about how much revenue for each of the 3 hospitals currently converted in the UK. The answer was obviously depending on which instruments they take but for a typical lap cholecystectomy would be about 1000 procedures annually with each lap cholecystectomy kit costing £100. The answer was given as £10k plus other items added in leading to £25k to £30k.For anyone with a gcse in maths 100 × 1000 =100000 = 100k.So each hospital would be 100k for the lap cholecystectomy kits over the year and not 10k as answered. I was just listening to the q&a section again. Gla. |
Posted at 25/3/2021 15:06 by jmf69 I thought it was a very useful and informative investor meeting. Happy to hold for now with things looking up particularly with increasing access to the USA market. |
Posted at 25/3/2021 09:14 by jmf69 https://www.investor |
Posted at 18/3/2021 09:20 by buywell3 The list of Institutional Investors in SUN reads better than some FTSE100 stocksThe percentage of SUN that is owned by these larger Investors is now very large So getting shares for the PI in any quantity is not too good and as better news of Distribution deals comes that gets harder still eg expect news re Dexter and other Robotics soon The market in the USA for Fix8 in 2023 will imo earn SUN about $1M Which means according to my maths === see previous posts re Trocar sales and SUN surgical instrument sales with USA Distributors Microline and Alder ( both 5yr deals) Means SUN should in buywells opine be turning over circa $6M plus from the USA alone in 2023 That is without new products which will be coming to market over the next 12 months -- Trocars and others This stock has only just started to play catch up imo That AMS has not moved to acquire it at these levels has surprised buywell , when Fix8 has FDA approval in 2022 --- then the Mkt Cap of SUN should have risen a fair bit higher than it is today dyor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
